We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

U.S. biotech sector shows IPO gains in 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

Biotech investments rise in Q4 2012, but remain off for the year

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology

MEI Pharma secures $27.5 million in commitments to develop cancer therapy

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 15 2012

According to a news source, San Diego-based oncology company MEI Pharma, Inc. is set to raise $27.5 million from commitments to purchase its stock and warrants in a private placement

Venture capitalists are returning to life-sciences investing

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

Reuters reports that a number of global venture firms have renewed their interest in the life sciences and health-care sectors, motivated by big acquisitions, U.S. laws speeding up certain drug approval processes and new products that have broadened the life-sciences definition

Venture capital investments increase in Q2 2012, but life science sector declines

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 30 2012

While PricewaterhouseCoopers MoneyTree report for the second quarter (Q2) of 2012 shows a double-digit increase in venture capital investment activity over the first quarter of the year, investments in life sciences declined

Court upholds drug profit sharing; pharma co. breached agreement to negotiate deal

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 7 2012

A Delaware court has issued a letter opinion finalizing its 2011 ruling requiring SIGA Technologies Inc. to share profits from its smallpox drug with PharmAthene, Inc. PharmAthene, Inc. v. SIGA Techs, Inc., No. 267-VCP (Del. Ch., decided May 31, 2012

New program to provide accelerated “speed-to-market” for medical device entrepreneurs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 1 2012

The nonprofit Memphis Bioworks Foundation and Innova, a pre-seed, seed and early-stage investor, have announced a program designed to help entrepreneurs bring medical device products and companies to market

Viropharma to acquire Swedish pharma in deal worth up to $164.6 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 3 2011

Pennsylvania-based ViroPharma Inc. has reportedly signed a deal to acquire Swedish company DuoCort Pharma AB to expand its orphan disease commercial product pipeline

Company secures $10 million in venture capital financing to improve DNA sequencing technology

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 22 2011

NABsys, Inc., a Rhode Island-based developer of electronic systems used for sequencing and analyzing single-molecule DNA, has reportedly raised $10 million in new venture capital funding, closing a Series C preferred stock financing round